Literature DB >> 36007522

Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα.

Dong Guo1, Yingying Tong2, Xiaoming Jiang1, Ying Meng1, Hongfei Jiang3, Linyong Du4, Qingang Wu1, Shan Li1, Shudi Luo1, Min Li1, Liwei Xiao1, Haiyan He1, Xuxiao He1, Qiujing Yu5, Jing Fang3, Zhimin Lu6.   

Abstract

High expression of PD-L1 in tumor cells contributes to tumor immune evasion. However, whether PD-L1 expression in tumor cells is regulated by the availability of nutrients is unknown. Here, we show that in human glioblastoma cells, high glucose promotes hexokinase (HK) 2 dissociation from mitochondria and its subsequent binding and phosphorylation of IκBα at T291. This leads to increased interaction between IκBα and μ-calpain protease and subsequent μ-calpain-mediated IκBα degradation and NF-κB activation-dependent transcriptional upregulation of PD-L1 expression. Expression of IκBα T291A in glioblastoma cells blocked high glucose-induced PD-L1 expression and promoted CD8+ T cell activation and infiltration into the tumor tissue, reducing brain tumor growth. Combined treatment with an HK inhibitor and an anti-PD-1 antibody eliminates tumor immune evasion and remarkably enhances the anti-tumor effect of immune checkpoint blockade. These findings elucidate a novel mechanism underlying the upregulation of PD-L1 expression mediated by aerobic glycolysis and underscore the roles of HK2 as a glucose sensor and a protein kinase in regulation of tumor immune evasion.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HK2; IκBα; NF-κB; PD-L1; glycolysis; immune evasion; phosphorylation; protein kinase

Mesh:

Substances:

Year:  2022        PMID: 36007522     DOI: 10.1016/j.cmet.2022.08.002

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   31.373


  1 in total

Review 1.  Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy.

Authors:  Chu Xiao; He Tian; Yujia Zheng; Zhenlin Yang; Shuofeng Li; Tao Fan; Jiachen Xu; Guangyu Bai; Jingjing Liu; Ziqin Deng; Chunxiang Li; Jie He
Journal:  Front Cell Dev Biol       Date:  2022-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.